Drug giant Pfizer isn’t ready to abandon neuroscience — here’s its $150-million ‘star cluster’ strategy for betting on promising brain drug startups

Execs from pharma giant Pfizer shared their strategy for keeping an eye on neuroscience — if not from the front row, then at least from the sidelines.